Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Bilous

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Human Pathology|November 17, 2009
HER-2 amplification is highly homogenous in gastric cancerMichael Bilous, Robert Y Osamura, J Rüschoff, et al.
American Journal of Clinical Pathology|September 19, 2009
Emerging technologies for assessing HER2 amplificationFrédérique Penault-Llorca, Michael Bilous, Mitch Dowsett, et al.
Asia-Pacific Journal of Clinical Oncology|December 24, 2016
Human epidermal growth factor receptor 2 status of gastric cancer patients in Asia: results from a large, multicountry studyNirmala Pathmanathan, Jing-Shu Geng, Wencai Li, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 7, 2012
HER2 testing in gastric cancer: a practical approachJosef Rüschoff, Wedad Hanna, Michael Bilous, et al.
Pathology|October 14, 2003
Supporting the implementation of breast pathology recommendations: feasibility of a feedback mechanism to pathologistsMaria I Torres, Fleur B Webster, A Michael Bilous, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 25, 2008
Re: High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring systemWedad M Hanna, Elizabeth Hammond, Clive R Taylor, et al.
Pathology|August 28, 2016
Determining HER2 (ERBB2) amplification status in women with breast cancer: final results from the Australian in situ hybridisation programAdrienne L Morey, Belinda Brown, Gelareh Farshid, et al.
Pathology|August 22, 2017
HER2 testing in advanced gastric and gastro-oesophageal cancer: analysis of an Australia-wide testing programM Priyanthi Kumarasinghe, Adrienne Morey, Michael Bilous, et al.
Pathology|December 23, 2009
A class discovery and class prediction approach to histopathological classification of mammographic screen detected columnar cell lesions of the breastNirmala Pathmanathan, Elizabeth L Salisbury, Pamela J Provan, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 18, 2010
Diagnostic evaluation of papillary lesions of the breast on core biopsyNirmala Pathmanathan, Ann-Flore Albertini, Pamela J Provan, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Human Pathology|November 17, 2009
HER-2 amplification is highly homogenous in gastric cancerMichael Bilous, Robert Y Osamura, J Rüschoff, et al.
American Journal of Clinical Pathology|September 19, 2009
Emerging technologies for assessing HER2 amplificationFrédérique Penault-Llorca, Michael Bilous, Mitch Dowsett, et al.
Asia-Pacific Journal of Clinical Oncology|December 24, 2016
Human epidermal growth factor receptor 2 status of gastric cancer patients in Asia: results from a large, multicountry studyNirmala Pathmanathan, Jing-Shu Geng, Wencai Li, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 7, 2012
HER2 testing in gastric cancer: a practical approachJosef Rüschoff, Wedad Hanna, Michael Bilous, et al.
Pathology|October 14, 2003
Supporting the implementation of breast pathology recommendations: feasibility of a feedback mechanism to pathologistsMaria I Torres, Fleur B Webster, A Michael Bilous, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 25, 2008
Re: High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring systemWedad M Hanna, Elizabeth Hammond, Clive R Taylor, et al.
Pathology|August 28, 2016
Determining HER2 (ERBB2) amplification status in women with breast cancer: final results from the Australian in situ hybridisation programAdrienne L Morey, Belinda Brown, Gelareh Farshid, et al.
Pathology|August 22, 2017
HER2 testing in advanced gastric and gastro-oesophageal cancer: analysis of an Australia-wide testing programM Priyanthi Kumarasinghe, Adrienne Morey, Michael Bilous, et al.
Pathology|December 23, 2009
A class discovery and class prediction approach to histopathological classification of mammographic screen detected columnar cell lesions of the breastNirmala Pathmanathan, Elizabeth L Salisbury, Pamela J Provan, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 18, 2010
Diagnostic evaluation of papillary lesions of the breast on core biopsyNirmala Pathmanathan, Ann-Flore Albertini, Pamela J Provan, et al.
Pageof 5